Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B (). „Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis”. Clin Neuropharmacol. 29 (2): 80–6. doi:10.1097/00002826-200603000-00005. PMID16614540.
drugbank.ca
„Lisuride”. DrugBank - Canadian Institutes of Health Research. Accesat în .
Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B (). „Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis”. Clin Neuropharmacol. 29 (2): 80–6. doi:10.1097/00002826-200603000-00005. PMID16614540.
web.archive.org
„Lisuride”. The American Society of Health-System Pharmacists. Arhivat din original la . Accesat în .
